

Patrick Verschueren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2557526/publications.pdf>

Version: 2024-02-01

152
papers

2,975
citations

159585

30
h-index

206112

48
g-index

154
all docs

154
docs citations

154
times ranked

3222
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: “Correspondence on “Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial” by Jain and Dhir <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e163-e163.	0.9	6
2	Correspondence on “EULAR recommendations for a core data set for pregnancy registries in rheumatology”. Annals of the Rheumatic Diseases, 2023, 82, e44-e44.	0.9	3
3	Psychosocial Burden Predicts Sustained Remission in Early Rheumatoid Arthritis: Unraveling the Complex Interplay of “Well-Being” and Disease Activity. Arthritis Care and Research, 2023, 75, 758-767.	3.4	14
4	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding” the British Society for Rheumatology guideline scope. Rheumatology, 2022, 61, 480-481.	1.9	0
5	Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial. Scandinavian Journal of Rheumatology, 2022, 51, 470-480.	1.1	8
6	P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage. Journal of Crohn's and Colitis, 2022, 16, i206-i207.	1.3	0
7	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. Annals of the Rheumatic Diseases, 2022, 81, 742-744.	0.9	7
8	JAK inhibition and the holy grail for pain control in early RA. RMD Open, 2022, 8, e002068.	3.8	1
9	Evaluation of Disease Burden by (Separate) Patient-reported, Clinical, and Laboratory Factor Scores in Patients With Established Rheumatoid Arthritis: A Factor Analysis Replication. Journal of Rheumatology, 2022, 49, 436-437.	2.0	2
10	P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). Journal of Crohn's and Colitis, 2022, 16, i482-i483.	1.3	0
11	Undifferentiated arthritis, not just another early manifestation of rheumatoid arthritis. Rheumatology, 2022, 61, 3101-3103.	1.9	3
12	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD Open, 2022, 8, e002099.	3.8	12
13	New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis. Rheumatology, 2022, 62, 108-115.	1.9	9
14	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 937-943.	0.9	14
15	Psychological stress in rheumatoid arthritis: a systematic scoping review. Seminars in Arthritis and Rheumatism, 2022, 55, 152014.	3.4	9
16	Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Annals of the Rheumatic Diseases, 2022, 81, 1379-1384.	0.9	2
17	Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response. Annals of the Rheumatic Diseases, 2022, 81, 1385-1391.	0.9	11
18	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the “JAK-pot” collaboration. Annals of the Rheumatic Diseases, 2022, 81, 1358-1366.	0.9	48

#	ARTICLE	IF	CITATIONS
19	IgA rheumatoid factor in rheumatoid arthritis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1617-1626.	2.3	6
20	Comment on: what is the best treatment for early rheumatoid arthritis?. <i>Rheumatology</i> , 2021, 60, e177-e178.	1.9	0
21	A mixed method study exploring patient satisfaction and feasibility of two exercise programmes in systemic sclerosis-associated microstomia. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab017.	0.7	3
22	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	13.7	145
23	From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8. <i>Frontiers in Immunology</i> , 2021, 12, 644725.	4.8	8
24	Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 965-973.	0.9	19
25	POS1434â€¦WHICH PROGNOSTIC FACTORS MIGHT PREDICT THE NEED FOR TREATMENT ADAPTATION IN EARLY RHEUMATOID ARTHRITIS? A COMPARISON OF MACHINE LEARNING, SURVIVAL ANALYSIS AND REGRESSION METHODS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1001.2-1002.	0.9	0
26	P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). <i>Journal of Crohn's and Colitis</i> , 2021, 15, S440-S440.	1.3	1
27	Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. <i>RMD Open</i> , 2021, 7, e001615.	3.8	13
28	POS0503â€¦THE DISCORDANCE BETWEEN PATIENT-REPORTED AND CLINICAL/BIOLOGICAL OUTCOMES COULD HELP IN PREDICTING FUTURE DISEASE IMPACT IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 484.1-484.	0.9	2
29	Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. <i>RMD Open</i> , 2021, 7, e001671.	3.8	13
30	Does opioid-based pharmacotherapy have a place in rheumatoid arthritis therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-3.	1.8	2
31	The ideal mHealth-application for rheumatoid arthritis: qualitative findings from stakeholder focus groups. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 746.	1.9	18
32	OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, 3699-3708.	1.9	10
33	Does Including Pain, Fatigue, and Physical Function When Assessing Patients with Early Rheumatoid Arthritis Provide a Comprehensive Picture of Disease Burden?. <i>Journal of Rheumatology</i> , 2021, 48, 174-178.	2.0	14
34	Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 269.	3.5	16
35	Belgian rheumatologistsâ€™ preferences regarding measures of disease activity in patients with rheumatoid arthritis: results from a mixed-methods study. <i>Rheumatology International</i> , 2021, , 1.	3.0	0
36	â€œMore than just chitchatâ€™: a qualitative study concerning the need and potential format of a peer mentor programme for patients with early rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001795.	3.8	8

#	ARTICLE	IF	CITATIONS
37	The perception of stakeholders on the applicability of nurse-led clinics in the management of rheumatoid arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, ii45-ii52.	0.7	5
38	Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids. <i>Frontiers in Immunology</i> , 2021, 12, 763832.	4.8	7
39	Response to Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, e6.	3.4	0
40	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	1.9	13
41	Fulminant macrophage activation syndrome in a patient with anti-synthetase syndrome. <i>Rheumatology</i> , 2020, 59, 1775-1777.	1.9	1
42	A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 873-878.	3.4	10
43	Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 672-680.	2.1	15
44	Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. <i>Rheumatology</i> , 2020, 59, .	1.9	1
45	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
46	One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. <i>RMD Open</i> , 2020, 6, e001146.	3.8	28
47	Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 556-565.	0.9	17
48	Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. <i>Clinical Rheumatology</i> , 2020, 39, 2593-2601.	2.2	1
49	FRI0596...NOVEL AUTOANTIBODY BIOMARKERS FOR THE PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 904.1-904.	0.9	0
50	SAT0028...THE FLARE-RA QUESTIONNAIRE CAN PREDICT FLARES IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS PARTICIPATING IN THE TAPER TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 944.3-944.	0.9	1
51	AB1209...A SYSTEMATIC REVIEW ON THE EFFECT OF DMARDS ON FERTILITY IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1896.2-1896.	0.9	0
52	AB1153...ANALGESIC AND ANTI-INFLAMMATORY DRUG USE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS VERSUS CONTROLS IN A BELGIAN GENERAL PRACTITIONER REGISTRY.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1867.1-1867.	0.9	0
53	The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz035.	0.7	11
54	Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa. <i>BMC Rheumatology</i> , 2019, 3, 37.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. <i>Rheumatology</i> , 2019, 58, 2284-2294.	1.9	42
56	Physical therapy in adult inflammatory myopathy patients: a systematic review. <i>Clinical Rheumatology</i> , 2019, 38, 2039-2051.	2.2	18
57	Primus inter pares: the choice of biologic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1325-1326.	1.9	1
58	Patient-Reported Outcome Data From an Early Rheumatoid Arthritis Trial: Opportunities for Broadening the Scope of Treating to Target. <i>Arthritis Care and Research</i> , 2019, 71, 1566-1575.	3.4	20
59	THU0094-...SERONEGATIVE RHEUMATOID ARTHRITIS: MILD NO MORE. , 2019, , .		0
60	SAT0135-...MAINTAINING REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS WHILE TAPERING ETANERCEPT: AN INSIGHT IN THE TAPERA TRIAL. , 2019, , .		1
61	FRI0668-...FIRST DATA OF THE TARDIS-RAREGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY. , 2019, , .		0
62	THU0138-...RHEUMATOLOGISTS'™ ADHERENCE TO THE TREAT-TO-TARGET PRINCIPLE IN EARLY RA PATIENTS WITHIN THE PRAGMATIC CARERA TRIAL: ROOM FOR IMPROVEMENT?. , 2019, , .		0
63	P290 Compliance to vaccination guidelines in patients with immune-mediated inflammatory diseases: a cross-sectional, single-centre study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S244-S245.	1.3	0
64	Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 667-677.	0.9	38
65	The use of glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1316-1317.	1.9	7
66	Rheumatoid granulomatous disease and pachymeningitis successfully treated with rituximab. <i>Acta Clinica Belgica</i> , 2018, 73, 307-312.	1.2	7
67	Dysphagia during glucocorticoid treatment of dermatomyositis: a differential diagnostic challenge. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky010.	0.7	0
68	222-€Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. <i>Rheumatology</i> , 2018, 57, .	1.9	1
69	SAT0214-...Effectiveness of a randomized step-down to methotrexate or leflunomide maintenance therapy in patients with low disease activity, 40 weeks after starting combined methotrexate-leflunomide remission induction therapy in early rheumatoid arthritis: results from the carera trial. , 2018, , .		1
70	THU0215-...Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. , 2018, , .		5
71	AB0292-...Autoantibodies to a novel peptide uh-ra.1 are associated with disease remission in rheumatoid arthritis. , 2018, , .		0
72	FRI0640-...Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis in three large independent cohorts. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	OP0034...Long-term effectiveness of the cobra slim remission induction and treat to target strategy in patients with early rheumatoid arthritis lacking classical markers of poor prognosis: 2 year results of the carera trial. , 2018, , .		0
74	Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Annals of the Rheumatic Diseases, 2017, 76, 511-520.	0.9	92
75	OP0226...Sustained effectiveness of methotrexate with step-down glucocorticoid remission induction (cobra slim) for early rheumatoid arthritis in a treat-to- target setting: 2-year results of the carera trial. , 2017, , .		0
76	Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. European Journal of Gastroenterology and Hepatology, 2017, 29, 84-90.	1.6	6
77	cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. Immunologic Research, 2017, 65, 307-325.	2.9	10
78	FRI0726...Long term use of analgesics and nsaid in early ra: lessons from the carera study. , 2017, , .		0
79	Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus Science and Medicine, 2017, 4, e000232.	2.7	12
80	Non-infective endocarditis with systemic embolization and recurrent stroke in systemic sclerosis. Rheumatology, 2016, 55, kev381.	1.9	1
81	Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?. Annals of the Rheumatic Diseases, 2016, 75, 947-949.	0.9	1
82	DÃ©veloppement dâ€™une matrice de risque de la progression radiographique rapide Ã 1 an aprÃ©s diagnostic dâ€™une polyarthrite rhumatoïde dâ€™adulte. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A249-A250.	0.0	0
83	Serum of patients with active rheumatoid arthritis inhibits differentiation of osteochondrogenic precursor cells. Connective Tissue Research, 2016, 57, 226-235.	2.3	1
84	Unraveling Patientâ€™Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study. Arthritis Care and Research, 2016, 68, 1278-1287.	3.4	45
85	Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. Scandinavian Journal of Rheumatology, 2016, 45, 171-178.	1.1	22
86	Systemic Inflammation Affects Human Osteocyte-Specific Protein and Cytokine Expression. Calcified Tissue International, 2016, 98, 596-608.	3.1	60
87	Should rheumatoid arthritis patients preferentially be treated with tocilizumab after rituximab failure?. Rheumatology, 2016, 55, 197-198.	1.9	0
88	OP0180...Remission Induction with Dmard Combinations and Glucocorticoids is not Superior to Remission Induction with MTX Monotherapy and Glucocorticoids: Week 52 Results of the High-Risk Group from the Carera Trial. Annals of the Rheumatic Diseases, 2015, 74, 139.2-139.	0.9	2
89	CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts. PLoS ONE, 2015, 10, e0131041.	2.5	41
90	A general practice perspective on early rheumatoid arthritis management: A qualitative study from Flanders. European Journal of General Practice, 2015, 21, 231-237.	2.0	18

#	ARTICLE	IF	CITATIONS
91	Patient experiences with intensive combination-treatment strategies with glucocorticoids for early rheumatoid arthritis. Patient Education and Counseling, 2015, 98, 384-390.	2.2	17
92	A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. Clinical Rheumatology, 2015, 34, 861-869.	2.2	12
93	Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clinical Rheumatology, 2015, 34, 1687-1695.	2.2	25
94	Mechanical Loading Reduces Inflammation-Induced Human Osteocyte-to-Osteoclast Communication. Calcified Tissue International, 2015, 97, 169-178.	3.1	36
95	Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Research and Therapy, 2015, 17, 97.	3.5	38
96	The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2015, 16, 1615-1625.	1.8	13
97	Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Annals of the Rheumatic Diseases, 2015, 74, 27-34.	0.9	106
98	Assessment of Activity Limitations with the Health Assessment Questionnaire Predicts the Need for Support Measures in Patients with Rheumatoid Arthritis: A Multicenter Observational Study. PLoS ONE, 2014, 9, e106749.	2.5	8
99	Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. Clinical Chemistry and Laboratory Medicine, 2014, 52, 547-51.	2.3	22
100	Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clinical Rheumatology, 2014, 33, 125-130.	2.2	17
101	A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 2014, 43, 1-8.	1.1	45
102	Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts. Osteoporosis International, 2014, 25, 2453-2463.	3.1	31
103	Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2014, 43, 265-272.	1.1	17
104	The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. Seminars in Arthritis and Rheumatism, 2014, 43, 627-631.	3.4	16
105	OP0137-HPRâ€¦Unravelling Preferred Outcomes of Disease and Treatment in Patients with Early Rheumatoid Arthritis: A Longitudinal Qualitative Interview Study. Annals of the Rheumatic Diseases, 2014, 73, 112.2-112.	0.9	3
106	THU0121â€¦Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial. Annals of the Rheumatic Diseases, 2014, 73, 220.1-220.	0.9	4
107	THU0137â€¦Associated with A Glucocorticoid Bridging Scheme, Methotrexate is as Effective Alone as in Combination with Other DMARDS for Early Rheumatoid Arthritis, with Fewer Reported Side Effects: 16 Weeks Remission Induction Data from the Carera Trial. Annals of the Rheumatic Diseases, 2014, 73, 226.2-226.	0.9	7
108	Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clinical and Experimental Rheumatology, 2014, 32, 71-6.	0.8	18

#	ARTICLE	IF	CITATIONS
109	Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clinica Chimica Acta, 2013, 415, 101-106.	1.1	50
110	Treatment of rheumatoid arthritis with methotrexate in Congolese patients. Clinical Rheumatology, 2013, 32, 1323-1327.	2.2	6
111	The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. Arthritis Research and Therapy, 2013, 15, R89.	3.5	10
112	Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Annals of the Rheumatic Diseases, 2012, 71, 180-185.	0.9	43
113	Antibodies to hnRNPs in patients with a systemic rheumatic disease with no antibodies to extractable nuclear antigens or dsDNA. Rheumatology, 2012, 51, 1515-1516.	1.9	0
114	The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. Rheumatology, 2012, 51, 1644-1647.	1.9	39
115	Defining remission in patients with RA in clinical practice. Nature Reviews Rheumatology, 2012, 8, 445-447.	8.0	4
116	Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmunity Reviews, 2012, 12, 137-143.	5.8	88
117	The Association of Illness Perceptions with Physical and Mental Health in Systemic Sclerosis Patients: An Exploratory Study. Musculoskeletal Care, 2012, 10, 18-28.	1.4	25
118	Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases. Arthritis and Rheumatism, 2012, 64, 213-221.	6.7	17
119	Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis. Clinical Rheumatology, 2012, 31, 367-373.	2.2	14
120	Septic Arthritis Due to Staphylococcus Warneri: A Diagnostic Challenge. Open Rheumatology Journal, 2012, 6, 23-30.	0.2	11
121	PAS-positive macrophages “not always infection. Lancet, The, 2011, 377, 1890.	13.7	8
122	Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmunity Reviews, 2011, 10, 801-808.	5.8	106
123	Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Annals of the Rheumatic Diseases, 2011, 70, 634-637.	0.9	20
124	Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology, 2011, 50, 1194-1200.	1.9	23
125	Antibodies to heterogeneous nuclear ribonucleoprotein H1 are directed to RNA recognition motif 3. Rheumatology, 2011, 50, 621-622.	1.9	0
126	The efficacy and safety of abatacept in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 89-94.	2.7	6

#	ARTICLE	IF	CITATIONS
127	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1655-1659.	0.9	10
128	CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2013-2016.	0.9	56
129	Anti-PM/Sci-100 and anti-RNA-polymerase III antibodies in scleroderma. <i>Clinica Chimica Acta</i> , 2010, 411, 965-971.	1.1	24
130	Heterogeneous Nuclear Ribonucleoprotein H1, a Novel Nuclear Autoantigen. <i>Clinical Chemistry</i> , 2009, 55, 946-954.	3.2	13
131	Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 287-289.	0.9	29
132	Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 166-172.	1.1	44
133	Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 117-123.	0.9	28
134	Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 759-761.	0.9	18
135	Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. <i>Musculoskeletal Care</i> , 2009, 7, 1-16.	1.4	28
136	Translating co-stimulation blockade into clinical practice. <i>Arthritis Research and Therapy</i> , 2008, 10, S4.	3.5	11
137	Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. <i>Rheumatology</i> , 2008, 48, 546-550.	1.9	5
138	Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. <i>Rheumatology</i> , 2008, 47, 59-64.	1.9	96
139	Technical and Diagnostic Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis. <i>Clinical Chemistry</i> , 2007, 53, 498-504.	3.2	147
140	Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. <i>Arthritis and Rheumatism</i> , 2007, 56, 3919-3927.	6.7	122
141	A new test set-up for skull fracture characterisation. <i>Journal of Biomechanics</i> , 2007, 40, 3389-3396.	2.1	32
142	Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2007, 26, 1969-1971.	2.2	96
143	Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 2205-2206.	2.2	39
144	Contemporary concepts of inflammation, damage and repair in rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 829-848.	3.3	80

#	ARTICLE	IF	CITATIONS
145	The presence of forefoot problems and the role of surgery in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2006, 65, 1254-1255.	0.9	46
146	Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery. Annals of the Rheumatic Diseases, 2006, 65, 694-695.	0.9	21
147	Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clinical Rheumatology, 2005, 24, 87-90.	2.2	31
148	A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Annals of the Rheumatic Diseases, 2004, 63, 1069-1074.	0.9	37
149	Diagnostic characteristics of a gelatin based Waaler-Rose assay (Serodia-RA) for the detection of rheumatoid factor. Annals of the Rheumatic Diseases, 2004, 63, 1169-1171.	0.9	7
150	Antistoffen tegen cyclisch gecitrullineerd peptide: een specifieke laboratoriumtest voor reumatoïde artritis. Tijdschrift Voor Geneeskunde, 2004, 60, 1167-1171.	0.0	0
151	Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Annals of the Rheumatic Diseases, 2003, 62, 368-369.	0.9	33
152	Increased cellularity and expression of adhesion molecules in muscle biopsy specimens from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. Annals of the Rheumatic Diseases, 2000, 59, 598-606.	0.9	7